Menu
GWAS Study

Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP.

Wigmore EM, Hafferty JD, Hall LS et al.

30700811 PubMed ID
GWAS Study Type
4229 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

WE
Wigmore EM
HJ
Hafferty JD
HL
Hall LS
HD
Howard DM
CT
Clarke TK
FC
Fabbri C
LC
Lewis CM
UR
Uher R
NL
Navrady LB
AM
Adams MJ
ZY
Zeng Y
CA
Campbell A
GJ
Gibson J
TP
Thomson PA
HC
Hayward C
SB
Smith BH
HL
Hocking LJ
PS
Padmanabhan S
DI
Deary IJ
PD
Porteous DJ
MO
Mors O
MM
Mattheisen M
NK
Nicodemus KK
MA
McIntosh AM
Chapter II

Abstract

Summary of the research findings

Antidepressants demonstrate modest response rates in the treatment of major depressive disorder (MDD). Despite previous genome-wide association studies (GWAS) of antidepressant treatment response, the underlying genetic factors are unknown. Using prescription data in a population and family-based cohort (Generation Scotland: Scottish Family Health Study; GS:SFHS), we sought to define a measure of (a) antidepressant treatment resistance and (b) stages of antidepressant resistance by inferring antidepressant switching as non-response to treatment. GWAS were conducted separately for antidepressant treatment resistance in GS:SFHS and the Genome-based Therapeutic Drugs for Depression (GENDEP) study and then meta-analysed (meta-analysis n = 4213, cases = 358). For stages of antidepressant resistance, a GWAS on GS:SFHS only was performed (n = 3452). Additionally, we conducted gene-set enrichment, polygenic risk scoring (PRS) and genetic correlation analysis. We did not identify any significant loci, genes or gene sets associated with antidepressant treatment resistance or stages of resistance. Significant positive genetic correlations of antidepressant treatment resistance and stages of resistance with neuroticism, psychological distress, schizotypy and mood disorder traits were identified. These findings suggest that larger sample sizes are needed to identify the genetic architecture of antidepressant treatment response, and that population-based observational studies may provide a tractable approach to achieving the necessary statistical power.

250 European ancestry cases, 3,202 European ancestry controls, 109 cases, 668 controls

Chapter III

Study Statistics

Key metrics and study information

4229
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
U.K.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.